The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

References

• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• BerryDACroninKAPlevritisSKCancer Intervention and Surveillance Modeling Network (CISNET) CollaboratorsEffect of screening and adjuvant therapy on mortality from breast cancerN Engl J Med20053531784179216251534
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerArch Pathol Lab Med2007131184319548375
   PubMed Web of Science ®Google Scholar
• RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist20091432036819346299
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNBreast Cancer International Research GroupAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• AnderssonMLidbrinkEBjerreKPhase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA studyJ Clin Oncol201129326427121149659
   PubMed Web of Science ®Google Scholar
• JohnstonSPippenJPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol200927335538554619786658
   PubMed Web of Science ®Google Scholar
• KaufmanBMackeyJRClemensMRTrastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM studyJ Clin Oncol200927335529553719786670
   PubMed Web of Science ®Google Scholar
• BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol2005233676368515738535
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohortLancet201037537738420113825
   PubMed Web of Science ®Google Scholar
• FriessTThierMScheuerWCombination treatment with pertuzumab and trastuzumab against Calu-3 human NSCLC xenograft tumors is superior to monotherapyPresented at: The 17th Annual Meeting of the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of CancerNovember 14–18, 2005Philadelphia, PA
   Google Scholar
• BaselgaJCortésJKimSBCLEOPATRA Study GroupPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• CortésJSwainSMKudabaIAbsence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelAnticancer Drugs201324101084109223969513
   PubMed Web of Science ®Google Scholar
• Pertuzumab product information2012 Available from: http://www.gene.com/download/pdf/perjeta_prescribing.pdf
   Google Scholar
• BaselgaJGelmonKAVermaSPhase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJ Clin Oncol20102871138114420124182
   PubMed Web of Science ®Google Scholar
• CortésJFumoleauPBianchiGVPertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201230141594160022393084
   PubMed Web of Science ®Google Scholar
• PorteraCCWalsheJMRosingDRCardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerClin Cancer Res20081492710271618451236
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJImSABiomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJ Clin Oncol201432333753376125332247
   PubMed Web of Science ®Google Scholar
• SwainSMKimSBCortésJPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyLancet Oncol201314646147123602601
   PubMed Web of Science ®Google Scholar
• SwainSKimSCortesJFinal overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancerPresented at: ESMO 2014September 28, 2014Madrid
   Google Scholar
• SwainSMBaselgaJMilesDIncidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRAAnn Oncol20142561116112124685829
   PubMed Web of Science ®Google Scholar
• DangCIyengarNDatkoFPhase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerJ Clin Oncol201533544244725547504
   PubMed Web of Science ®Google Scholar
• PerezELopez-VegaJMastroLA combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, phase II study (VELVET)J Clin Oncol201230Suppl15
   Google Scholar
• BachelotTCiruelosEPeretz-YablonskiTFirst-line pertuzumab, trastuzumab, and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer: Interim safety results (N=704) from PERUSEPresented at: The 50th American Society of Clinical Oncology Annual MeetingMay 30–June 3, 2014Chicago, IL Poster #548
   Google Scholar
• MillerKDDiérasVHarbeckNPhase II trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerJ Clin Oncol201432141437144424733796
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHeggREvaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHA-ENA studyBreast Cancer Res2014164R7325005255
   PubMed Web of Science ®Google Scholar
• SwainSMEwerMSCortésJCardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studyOncologist201318325726423475636
   PubMed Web of Science ®Google Scholar
• CortésJBaselgaJImYHHealth-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancerAnn Oncol201324102630263523868905
   PubMed Web of Science ®Google Scholar
• ValachisANearchouAPolyzosNPCardiac toxicity in breast cancer patients treated with dual HER2 blockadeInt J Cancer20131332245225223629633
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLEMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med20123671783179123020162
   PubMed Web of Science ®Google Scholar
• GiordanoSTeminSKirshnerJAmerican Society of Clinical OncologySystemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201432192100210824799487
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar